AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read

Levy Raphi sold $43K of DRTS

Levy Raphi (Chief Financial Officer) sold 2,871 shares of Alpha Tau Medical Ltd. (DRTS) at $15.00 on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Levy Raphi
Published Aug 25, 2026, 2:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$DRTS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The transaction represents a modest $43K divestiture, unlikely to move the stock.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

potential future 10b5-1 sales could accumulate

Relevance 2/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing reports a CFO's open‑market sale of 2,871 shares of Alpha Tau Medical Ltd.

Market effects

Sector

minimal impact on medical device sector

Regional

none

Global

none

Counterpoint

What could challenge this read

sale size is trivial; may not signal insider concern

Key entities

  • Company
    Alpha Tau Medical Ltd.

    Medical device company, ticker not confirmed as US‑listed

  • Insider
    Levy Raphi

    Chief Financial Officer of Alpha Tau Medical

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DRTS insider trading history →

Related articles

JUL 21
$DRTSMedAI 8/10

Alpha Tau Shows 100% ORR With Alpha DaRT Plus Keytruda In Head And Neck Squamous Cell Carcinoma

Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.

rttnews.com4 min
JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min